ERBB2 and breast carcinoma: Furthermore, looking into the future of HER2 assessment in breast cancer, it will be essential to carefully evaluate the integration of mRNA-based assays with existing methodologies, such as immunohistochemistry and fluorescence in situ hybridisation, to establish the most effective diagnostic approach.